Come up with a name for your new list and we'll add to it:
Samumed raised a round of funding on January 02, 2012. Investors include
Vickers Venture Partners.
Samumed, formerly known as Wintherix & Epitherix, has identified a number of novel drug compounds to selectively activate or inhibit the Wnt pathway toward regenerative medicine and treatment of oncol…